The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma

Cancer Prevention Research

Volumn 5, Issue 1, 2012, Pages 61-72

  Chan, Andrew T ^a,b   Hsu, Meier ^d   Zauber, Ann G ^d   Hawk, Ernest T ^e   Bertagnolli, Monica M ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; GLUCURONOSYLTRANSFERASE 1A6; PLACEBO;

ADULT; AGED; ARTICLE; CANCER RISK; COLONOSCOPY; COLORECTAL ADENOMA; CONFIDENCE INTERVAL; DRUG EFFECT; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GENETIC VARIATION; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PYRAZOLES; SULFONAMIDES;

EID: 84855534328     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0337     Document Type: Article

References (21)

1. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9. (Pubitemid 36297997)
2. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90. (Pubitemid 36297996)
3. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36. (Pubitemid 36929412)
4. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29-38. (Pubitemid 350309319)
5. BertagnolliMM,Eagle CJ, Zauber AG, Redston M,Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84. (Pubitemid 44315980)
6. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95. (Pubitemid 44315981)
7. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80. (Pubitemid 40365348)
8. Hutt AJ, Caldwell J, Smith RL. The metabolism of aspirin in man: a population study. Xenobiotica 1986;16:239-49. (Pubitemid 16164017)
9. Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 1997;7:485-95. (Pubitemid 27517577)
10. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001;61:3566-9. (Pubitemid 32694961)
11. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst 2005;97:457-60. (Pubitemid 40528609)
12. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res 2009;2:310-21.
13. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. A prospective study of genetic polymorphisms in the cytochrome P450 2C9 enzyme and the risk of distal colorectal adenoma. Clin Gastro Hepatol 2004;2:704-12. (Pubitemid 39013431)
14. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. Hoboken NJ: Wiley; 2002.
15. Delong DM, Guirguis GH, So YC. Efficient computation of subset selection probabilities with application to Cox regression. Biometrika 1994;81:607-11.
16. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 2009;136: 2127-36 e1.
17. Hubner RA, Muir KR, Liu J-F, Logan RFA, Grainge M, Armitage N, et al. Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence. Clin Cancer Res 2006;12:6585-9. (Pubitemid 44799734)
18. Samowitz WS, Wolff RK, Curtin K, Sweeney C, Ma KN, Andersen K, et al. Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol 2006;4:894-901. (Pubitemid 43994544)
19. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
20. Arber N, Spicak J, Racz I, Zavoral M, Breazna A, Gerletti P, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol 2011;106:1135-46.
21. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195-8. (Pubitemid 351212675)